Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness and Safety of Benralizumab in Allergic Bronchopulmonary Aspergillosis (ABPA): a Prospective Study of Real-world Experience

NCT07530770 is registered in ClinicalTrials.gov with Qianfoshan Hospital as lead sponsor.

NCT NCT07530770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07530770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness and Safety of Benralizumab in Allergic Bronchopulmonary Aspergillosis (ABPA): a Prospective Study of Real-world Experience
Lead sponsor
Qianfoshan Hospital
Phase
Observational
Overall status
Recruiting
Start date
September 1, 2025
Completion date
December 1, 2026
Enrollment
20 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

abpa, allergic bronchopulmonary aspergillosis, severe asthma